Adults 22 to 65, any sex, with Stress Disorders, Post-Traumatic. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number, Severity, Relatedness, Type, Subsequent Treatment/Intervention Required, and Resolution Status of Adverse Events (AEs) During the Study.Primary· Baseline and Final Measure, between 10-21 Days
Number - Number of adverse events reported. Note that each participant may have had more than one adverse event (AE).
Severity - Number of adverse events that were mild, moderate, or severe. Relatedness - Number of adverse events that were not related, suspected, or definitely related to treatment.
Type - Number of adverse events that were or were not Serious Adverse Events (SAEs).
Subsequent treatment/intervention required - Number of adverse events that did or did not require subsequent treatment/intervention.
Number of participants reporting at least one AE
Adverse Event Intensity - Mild
Group
Value
95% CI
Open-Label Active EEG-based Personalized TMS Treatment
26
Adverse Event Intensity - Moderate
Group
Value
95% CI
Open-Label Active EEG-based Personalized TMS Treatment
3
Adverse Event Intensity - Severe
Group
Value
95% CI
Open-Label Active EEG-based Personalized TMS Treatment
2
Adverse Event Relationship to Treatment - Not Related
Group
Value
95% CI
Open-Label Active EEG-based Personalized TMS Treatment
17
Adverse Event Relationship to Treatment - Suspected
Group
Value
95% CI
Open-Label Active EEG-based Personalized TMS Treatment
5
Adverse Event Relationship to Treatment - Definitely Related
Group
Value
95% CI
Open-Label Active EEG-based Personalized TMS Treatment
9
Serious Adverse Event
Group
Value
95% CI
Open-Label Active EEG-based Personalized TMS Treatment
0
Not a Serious Adverse Event
Group
Value
95% CI
Open-Label Active EEG-based Personalized TMS Treatment
31
Improvement in PTSD Symptoms as Measured by Drop in Score on the PTSD Checklist for DSM-5 (PCL-5)Secondary· Baseline and Final Measure, between 10-21 Days
The Post Traumatic Stress Disorder (PTSD) Checklist for Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. (DSM-5), commonly referred to as PCL-5, is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. It is used to monitor symptom change during and after treatment. Each item is scored from 0 to 5 as the participant's estimate of the severity of the symptom (0 = Not at all, 1=A little bit, 2 = Moderately, 3 = Quite a bit, 4 = Extremely). The final score range is between 0-80. A lower score is considered better than a higher score.
Baseline Measure
Group
Value
95% CI
Open-Label Active EEG-based Personalized TMS Treatment
52.2
± 8.9
Final Measure
Group
Value
95% CI
Open-Label Active EEG-based Personalized TMS Treatment
22.9
± 14.0
Change between Baseline and Final Measure
Group
Value
95% CI
Open-Label Active EEG-based Personalized TMS Treatment
29.3
± 13.1
Number of Participants With at Least One Adverse EventSecondary· Baseline and Final Measure, between 10-21 Days
The number of participants who experienced at least one Adverse Event in the study
Group
Value
95% CI
Open-Label Active EEG-based Personalized TMS Treatment
14
Adverse events — posted to ClinicalTrials.gov
Time frame: Baseline and Final Measure, between 10-21 Days. In addition, any adverse events that occurred after the Final Measure until Study completion were included..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Open-Label Active EEG-based Personalized TMS Treatment
This is an open-label safety pilot study of the Electroencephalogram (EEG) Transcranial Magnetic Stimulation (eTMS) treatment for Post-Traumatic Stress Disorder (PTSD). The recruitment goal is 30 participants who are United States Military veterans or first responders (e.g., firefighters, police, paramedics, etc.). The Study includes an EEG recording in order to determine the optimal treatment parameters for the eTMS system, followed by 10 in-office visits that take place over 21 total days. Two eTMS treatment sessions are administered during each office visit.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06892028 — EEG-based Personalized Transcranial Magnetic Stimulation (eTMS) to Treat Post-Traumatic Stress Disorder
· NA
· recruiting
Other recruiting trials for Stress Disorders, Post-Traumatic
Currently open trials in the same condition.
NCT07422077 — Impact of ERCS on Perceived Stress in Patients Hospitalized in the Post-resuscitation Rehabilitation Service
· NA
· recruiting
NCT07010770 — SMART Therapist Training: A Hybrid Factorial-SMART Design
· NA
· recruiting
NCT06852469 — Computational Assessment of GABA Receptor Modulation in PTSD
· Phase 4
· recruiting
NCT06000475 — Enhancing Memory in CPT for PTSD
· NA
· recruiting
NCT06355284 — Overcontrol and Suicide in PTSD
· active not recruiting
Other Wave Neuroscience trials
Trials by the same sponsor.
NCT06892028 — EEG-based Personalized Transcranial Magnetic Stimulation (eTMS) to Treat Post-Traumatic Stress Disorder
· NA
· recruiting
NCT02990793 — Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder
· NA
· completed
NCT03288714 — Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder
· NA
· completed
NCT03066505 — A Randomized, Double-blind, Sham-controlled Pilot Study to Evaluate the Treatment Efficacy of Magnetic EEG/ECG-Guided Re
· NA
· completed
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wave Neuroscience
Last refreshed: 19 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06081309.